Drug Trial Radar · NCT01047540
Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2
Last checked: Nov 19, 2026Latest source record: Apr 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
156
Actual
Start
Mar 2010
Primary completion
Dec 2010
Study completion Mar 2011
Sponsor
- Lead sponsor
- AiCuris Anti-infective Cures AGIndustry
- Sponsor type
- Industry
- Collaborators
- FHI 360
- First posted
- Jan 13, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes
Conditions
- HSV-2
Interventions
AIC316Drug
Oral administration
AIC316Drug
Oral administration
AIC316Drug
Oral administration
AIC316Drug
Oral administration
PlaceboDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of 4 Different Doses of AIC316 and Matching Placebo With Respect to the Suppression of Herpes Simplex Virus Replication (Shedding Rate)Time frame: 28 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Cetero Research Miami Gardens
Miami, Florida
Indiana University School of Medicine, Office for Research
Indianapolis, Indiana
Westover Heights Clinic
Portland, Oregon
University of Texas Health Science Centre, Center for Clincial Studies
Houston, Texas
University of Utah
Salt Lake City, Utah
University of Washington, Virology Research Clinic
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.